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Abstract
Background: Early studies with desloratadine demonstrated efficacy in treating seasonal allergic
rhinitis (SAR). A dose-ranging study was conducted to characterize its 24-hour efficacy in patients
with SAR.
Methods: Patients (N = 1,026) were randomly assigned once-daily (QD) desloratadine (2.5, 5, 7.5,
10, or 20 mg) for 2 weeks in a placebo-controlled, double-blind study. The end point of 24-hour
efficacy was assessed by the mean change from baseline in the average AM instantaneous total
symptom score (TSS) over the treatment period. Day 2 data were assessed for efficacy of
desloratadine following the first dose. Other efficacy variables included AM/PM previous total nasal
and nonnasal symptom scores and individual symptom scores.
Results: Desloratadine 5–20 mg was significantly (P < .01) more effective than placebo in improving
total AM instantaneous TSS and AM/PM previous total nasal and nonnasal symptom scores. This
dosing range also was significantly (P < .01) more effective than placebo for reducing AM
instantaneous TSS beginning with the first dose; thus, demonstrating the full 24-hour efficacy of
desloratadine. AM/PM previous scores for all individual symptoms, including nasal congestion, were
also significantly improved versus placebo (P < .05) with desloratadine at 5, 7.5, and 20 mg. All
treatments were well tolerated. There were no clinically meaningful changes in electrocardiogram
parameters.
Conclusion:  Desloratadine 5–20 mg provided significant 24-hour relief of SAR signs and
symptoms. There were no statistically significant differences between the 4 largest doses suggesting
that desloratadine 5 mg QD offers the best therapeutic profile for patients with SAR.
Background
Second-generation oral antihistamines are among the
most widely prescribed agents in the United States and
Europe due to their effectiveness in the treatment of aller-
gic diseases. Although newer long-acting antihistamine
preparations permit once-daily dosing, many patients
with seasonal allergic rhinitis (SAR) experience break-
through symptoms and a diminution of clinical potency
at the end of the dosing interval. Most antihistamines
demonstrate a peak effect approximately 5 to 7 hours after
oral administration, and the duration varies depending
on the elimination half-life [1].
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Desloratadine, a new nonsedating antihistamine, was re-
cently approved by the Food and Drug Administration.
This agent has a very high affinity for histamine1 (H1)-re-
ceptors and a very low affinity for H2 and muscarinic re-
ceptors [2]. Unlike other antihistamines, desloratadine
does not have clinically significant pharmacokinetic or
pharmacodynamic interactions with drugs that inhibit the
cytochrome P-450 system or the p-glycoprotein transport
system [3]. Desloratadine has a long half-life of approxi-
mately 27 hours [4,5]. Earlier reports suggested that
desloratadine has 24-hour efficacy in patients with SAR
[6,7] and in patients with chronic idiopathic urticaria [8].
This hypothesis was further explored by analysis of data
from a large placebo-controlled dose-ranging study in
subjects with SAR that characterized the efficacy of five
once-daily desloratadine regimens (2.5 to 20 mg/d) at the
end of the 24-hour dosing interval.
Methods
Participants
Subjects 12 years or older with a 2-year documented his-
tory of SAR and otherwise in good health were eligible for
enrollment. All subjects had a positive skin test response
to an appropriate tree and/or grass seasonal allergen with-
in the 12 months before study initiation. Subjects were
determined to be in good health based on medical histo-
ry, physical examination, electrocardiogram (ECG), and
routine laboratory tests (blood chemistry, complete blood
count, and urinalysis). Women of childbearing potential
agreed to use a medically accepted method of contracep-
tion during this study. All subjects, as well as a parent or
guardian when appropriate, provided written informed
consent.
At the screening and baseline visits, the signs and symp-
toms of allergic rhinitis were scored jointly by the investi-
gator and subject (with assistance from the parent/
guardian, if required). Evaluated nasal symptoms includ-
ed rhinorrhea, nasal stuffiness/congestion, nasal itching,
and sneezing. Evaluated nonnasal signs and symptoms in-
cluded itching/burning eyes, tearing/watering eyes, red-
ness of eyes, and itching of ears or palate. All symptoms
were graded on a 4-point scale using the following system:
0 = none, 1 = mild, 2 = moderate, and 3 = severe. For in-
clusion on the study, subjects had to have a nasal rhinor-
rhea score of at least 2, a total nasal symptom score of at
least 6, and a total nonnasal score of at least 5.
Subjects who met the following criteria were excluded
from participation: (1) chronic use of inhaled or systemic
corticosteroids for treatment of asthma; (2) current or past
history of clinically significant sinusitis or chronic puru-
lent postnasal drip; (3) rhinitis medicamentosa; (4) a his-
tory of allergies to more than 2 classes of medications; (5)
hypersensitivity to or intolerance of antihistamines; (6)
an upper respiratory tract or sinus infection that required
antibiotic treatment within the 14 days before study
screening; (7) a viral upper respiratory infection within 7
days before study screening; (8) nasal structural abnor-
malities that significantly interfered with nasal air flow;
(9) dependence on nasal, oral, or ocular decongestants,
nasal topical antihistamines, or nasal corticosteroids; (10)
use of immunotherapy unless on a regular maintenance
schedule before screening and maintained on a schedule
for the remainder of the study; (11) hypersensitivity to the
study drug or its excipients; and (12) current pregnancy or
lactation.
Study Design
This was a randomized, multicenter, parallel-group, pla-
cebo-controlled, double-blind study. The study was con-
ducted at 29 medical centers across the United States.
Following an approximately 1-week screening period, eli-
gible subjects were randomly assigned in a 1:1:1:1:1:1 ra-
tio to 2 weeks of treatment with desloratadine, 2.5, 5, 7.5,
10, or 20 mg, or placebo. Randomization was performed
in blocks of 6 using a computer-generated randomization
schedule. Each dose of study drug was administered orally
in the morning, at approximately the same time each day.
There were 5 scheduled study visits; a screening visit, a
baseline visit on treatment day 1, and follow-up visits on
days 4, 8, and 15. A central institutional review board
and/or a local ethical committee approved the study be-
fore initiation.
To ensure blinding, the desloratadine and placebo tablets
were identical in appearance and were packaged identical-
ly. Each daily dose consisted of 2 tablets. Desloratadine
and placebo tablets were supplied by Schering Corpora-
tion, Kenilworth, NJ. Compliance with study medication
was assessed at each study visit by questioning the subject,
reviewing the diary cards, and examining the subject's
drug supply.
Use of the following medications was prohibited during
the study: nasal cromolyn sodium, nedocromil, saline, at-
ropine, ipratropium bromide, azelastine, and corticoster-
oids; oral corticosteroids, antihistamines, and
decongestants; ocular decongestants, corticosteroids, and
saline; topical anti-inflammatory agents; and inhaled, in-
travenous, rectal, intramuscular, or intra-articular corti-
costeroids, as well as high-potency dermatologic
corticosteroids. Use of systemic antibiotics was also pro-
hibited, unless the patient was on a stable dose. There was
a prespecified washout period for each of the prohibited
medications, ranging from 12 hours for ocular and nasal
saline to 3 months for intramuscular or intra-articular cor-
ticosteroids. Patients were able to take any medication
that was not restricted by the protocol and that would not
be expected to interfere with the study. AcetaminophenBMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/14
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was permitted to be taken as needed for appropriate indi-
cations.
Clinical outcome assessment
Beginning at least 3 days before the baseline visit and
throughout the remainder of the study, subjects recorded
the severity of their nasal and nonnasal symptoms twice
daily based upon how they felt the previous 12 hours (re-
flective) and also at the time of assessment (instantane-
ous). The nasal (rhinorrhea, nasal stuffiness/congestion,
nasal itching, and sneezing) and nonnasal (itching/burn-
ing eyes, tearing/watering eyes, redness of eyes, and itch-
ing of ears or palate) symptoms were individually graded
using a 4-point scale (0 = none to 3 = severe). The total
symptom score was the sum of the scores for the 4 nasal
and 4 nonnasal symptoms.
To characterize the efficacy of desloratadine at the end of
the dosing interval, 24-hour efficacy of the study medica-
tions was evaluated using the AM instantaneous data set
(before the next morning dose). The primary outcome of
this analysis was the 2-week average AM instantaneous to-
tal symptom score expressed as a mean change from base-
line. Secondary outcomes included the mean AM/PM
previous total nasal and total nonnasal scores and indi-
vidual symptom scores. In addition, day 2 AM instantane-
ous total symptom scores were analyzed to assess the
effectiveness of desloratadine 24 hours after the first dose.
Diary cards also were used to record use of study medica-
tion, use of concomitant medication, adverse events, and
the daily number of hours the subject was exposed to out-
side air. The diary cards were collected and reviewed at
each visit.
Statistical analysis
All randomized subjects who received at least 1 dose of
study medication and had baseline and at least 1 post-
baseline day of diary data were included in the primary in-
tent-to-treat efficacy analyses. The safety analyses included
all randomized subjects. Before combining data across
centers, center-specific results were examined and the sig-
nificance of the treatment-by-center interaction for the
primary efficacy variable was examined. Data were ana-
lyzed using a two-way analysis of variance (ANOVA) that
extracted sources of variation due to treatment and center.
The primary comparison was based on the pairwise differ-
ences in least-squares means between desloratadine, 10
mg, and placebo (from the ANOVA) using a 5% signifi-
cance level. If the desloratadine 10-mg treatment was sig-
nificantly different from placebo, then all other doses of
desloratadine were compared with placebo at the 5%
(two-sided) level of significance without adjustment for
the multiple comparisons. In addition, a test of trend for
nondecreasing response with increasing desloratadine
dose (0, 2.5, 5, 7.5, 10, and 20 mg) was evaluated using
the same two-way ANOVA.
The study was designed to enroll 150 subjects per treat-
ment group. The sample size was chosen to detect (with
90% power and a 5% significance level) a difference be-
tween treatment groups of 1.6 units or more in the mean
change from baseline diary total symptom score, assum-
ing a pooled SD of 4.25.
Safety assessment
Laboratory tests (complete blood count, blood chemistry,
urinalysis) were performed and a 12-lead ECG was ob-
tained at screening and at the conclusion of the study. Vi-
tal signs and adverse events were evaluated at each study
visit.
Table 1: Summary of Demographic Data and Disease Characteristics at Baseline (all randomized subjects)
Desloratadine
Characteristic 2.5 mg
 (n = 173)
5 mg
 (n = 172)
7.5 mg
 (n = 173)
10 mg
 (n = 172)
20 mg
 (n = 172)
Placebo
 (n = 174)
Mean (range) age, years 34 (13–73) 34 (12–75) 34 (12–73) 34 (12–70) 34 (12–72) 35 (12–63)
Age group, years
12–17 22 26 25 28 25 22
18–65 150 143 145 143 145 152
> 6 5 13 3 120
Sex
Male 73 68 68 71 62 81
Female 100 104 105 101 110 93
Mean duration (range) of seasonal allergic 
rhinitis, years
18 (2–60) 18 (2–55) 16 (2–50) 17 (2–49) 16 (2–48) 17 (2–50)BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/14
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Results
Patient disposition and demographics
Between April 1998 and June 1998, a total of 1,036 sub-
jects was randomized to treatment; 10 subjects lacked
baseline or postbaseline data and were excluded from the
intent-to-treat analyses. For the 2.5-mg, 5-mg, 7.5-mg, 10-
mg, 20-mg, and placebo groups, 2, 1, 1, 2, 3, and 1, pa-
tients were excluded, respectively. Fifty-eight subjects dis-
continued the study. There was no apparent differential
incidence of discontinuation rates among the treatment
groups. Treatment failure led to discontinuation among
3% of the placebo and desloratadine 2.5-mg groups and
1% to 2% of the remaining active treatment groups. Dis-
continuations due to adverse events were similar across all
study groups, including placebo, and are discussed further
next. The demographic and baseline disease characteris-
tics of the treatment groups were similar (Table 1).
Efficacy analyses
The changes from baseline in subject-evaluated AM in-
stantaneous total symptom scores averaged over the 2-
week treatment period for once-daily desloratadine doses
of 5, 7.5, 10, and 20 mg were all superior to placebo (P <
.01; Figure 1); the 2.5-mg dose was numerically superior
to placebo (P = not significant). Efficacy was maintained
24 hours after administration of the first dose (day 2 as-
sessment) when once-daily desloratadine doses of 5, 7.5,
10, and 20 mg significantly reduced AM instantaneous to-
tal symptom scores compared with placebo (P < .01; Fig-
ure 2). No statistically significant differences were found
when comparing desloratadine 5-, 7.5-, 10-, and 20-mg
doses with each other.
Upon examination of the mean change from baseline in
subject-evaluated AM/PM previous total nasal and nonna-
sal symptom scores averaged over the 2-week treatment
period, desloratadine doses of 5, 7.5, 10, and 20 mg were
all superior to placebo (P < .01). During this interval,
mean reductions in AM/PM previous total nasal symptom
scores for the desloratadine groups were 1.6 for 2.5 mg,
2.2 for 5 mg, 2.3 for 7.5 mg, 2.0 for 10 mg, and 2.5 for 20
mg; the placebo group had a 1.4 reduction. The 5-, 7.5-,
and 20-mg doses of desloratadine were all significantly (P
< .01) more effective than the placebo in reducing subject-
evaluated total nasal symptom scores. Mean reductions in
AM/PM previous total nonnasal symptoms averaged over
the 2-week treatment period were 1.6 with desloratadine
2.5 mg, 2.1 with desloratadine 5 and 7.5 mg, 1.9 with
desloratadine 10 mg, 2.3 with desloratadine 20 mg, and
1.2 with placebo.
Over the 2-week study period, mean AM/PM previous
scores for all 8 individual symptoms, including nasal con-
gestion/stuffiness, showed statistically significant im-
Figure 1
Mean change in AM instantaneous symptom scores for desloratadine 2.5-, 5-, 7.5-, 10-, and 20-mg tablets compared with pla-
cebo for days 2–15. Mean changes from baseline are least-square means based on ANOVA model with treatment and center
effects. TSS = total symptom score is nasal + nonnasal scores. (*P < .01 versus placebo.)BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/14
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provements versus placebo (P < .05 to P  ≤  .01) with
desloratadine doses of 5, 7.5, and 20 mg. The 10-mg dose
of desloratadine showed numerical improvement versus
placebo in all 8 individual symptom scores and signifi-
cantly reduced (P < .05 versus placebo) nasal itching and
sneezing, itching/burning eyes, tearing/watering eyes, and
itching of ears or palate.
Safety evaluation
All treatments were well tolerated; there were no unusual
or unexpected adverse events. Treatment-related adverse
events were reported by approximately 15% to 22% of
subjects in the desloratadine group compared with 14%
for the placebo group. The overall incidence of adverse
events was similar among all 6 treatment groups (includ-
ing placebo); there were no apparent dose-related trends
in the adverse events. The majority of adverse events were
mild or moderate in severity. Headache, somnolence, and
fatigue were the most frequently reported adverse events.
The incidence of headache in the 2.5-mg, 5-mg, 7.5-mg,
10-mg, and 20-mg desloratadine groups was 9%, 6%, 7%,
7%, and 8%, respectively; the incidence with placebo was
5%; somnolence was 3%, 2%, 4%, 3%, and 6%, respec-
tively for desloratadine and 2% with placebo. Treatment-
related fatigue was reported in 2%, 2%, 3%, 4%, and 4%,
respectively for the desloratadine group and <1% for the
placebo group.
Twenty subjects did not complete the study because of ad-
verse events. There was no apparent pattern of occurrence
with respect to treatment group, and no particular risk was
associated with active treatment at any dosage. Approxi-
mately half the adverse events resulting in study discon-
tinuation were due to concurrent illness and were
considered unrelated to study treatment by the investiga-
tor. The other discontinuations were due to a wide variety
of adverse events that were considered at least possibly re-
lated to treatment by the investigator; none of these events
was reported by more than 3 subjects who discontinued
treatment. There were no clinically relevant changes in
median laboratory test values or vital signs and no clini-
cally significant changes in mean ECG parameters, includ-
ing QTc intervals, with any dose of desloratadine.
Discussion
This study demonstrates that once-daily desloratadine
therapy at the approved 5-mg dose is significantly more
effective than placebo in relieving the symptoms of SAR
and retains its effectiveness to the end of the once-daily
dosing interval. Moreover, full 24-hour efficacy was ap-
parent after the first dose. Desloratadine doses of 5, 7.5,
Figure 2
Mean change in AM instantaneous total symptom scores for desloratadine 2.5-, 5-, 7.5-, 10-, and 20-mg tablets compared with
placebo after the first dose (day 2). Mean changes from baseline are least-square means based on ANOVA model with treat-
ment and center effects. Total symptom score is nasal + nonnasal scores. (*P < .01 versus placebo.)BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/14
Page 6 of 6
(page number not for citation purposes)
10, and 20 mg were similarly effective, significantly reduc-
ing the nasal and nonnasal symptoms of SAR for a full 24
hours.
Previous studies have attempted to evaluate the efficacy of
antihistamines at the end of the dosing interval by assess-
ing nasal airway resistance following nasal challenge with
histamine,[9] the wheal-and-flare response following epi-
cutaneous administration of histamine,[10,11] and sub-
jective and objective responses in patients exposed to
pollen in the Vienna Challenge Chamber.[12] Although
these studies have demonstrated some effects at the end of
the dosing interval, the clinical relevance of the employed
methods has not been established. By contrast, this is the
first dose-ranging study that demonstrates the efficacy of
an antihistamine at the end of the dosing interval. The pa-
rameters used to assess efficacy at the end of the dosing in-
terval in this study provide clinically meaningful
information that supports the 24-hour control of
desloratadine. The overall incidence of adverse events re-
ported with desloratadine during this study was compara-
ble to that with placebo. Use of desloratadine was not
associated with any clinically meaningful changes in ECG
results, including the critical QTc interval.
Conclusions
In conclusion, desloratadine provided 24-hour relief of
the signs and symptoms of SAR, with no statistically sig-
nificant differences between the 5-, 7.5-, 10-, and 20-mg
doses. All desloratadine doses were well tolerated. Be-
cause there were no significant differences in efficacy or
safety, a 5-mg once-daily dose of desloratadine appears to
be optimal for the treatment of SAR, providing full 24-
hour efficacy beginning with the first dose and main-
tained over the 2-week study period.
Abbreviations
SAR = seasonal allergic rhinitis; H1 = histamine1; ECG =
electrocardiogram; ANOVA = analysis of variance; SD =
standard deviation.
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